By Fineline Cube 
US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG: 1801), granting the Chinese company non-exclusive worldwide rights to use GlycoT’s site-specific antibody bioconjugation technology. The deal enables Innovent to develop, manufacture, and commercialize antibody-drug conjugate (ADC) products.
Collaboration Framework
Under the collaboration, GlycoT will provide technical support during the R&D phase, while Innovent will share certain predefined preclinical data with GlycoT. The deal includes undisclosed upfront and milestone payments.
Technology Integration
This partnership introduces GlycoT’s unique “One-Pot Single-Enzyme” technology to Innovent’s existing ADC platform. The technology enhances ADC research capabilities, provides deeper insights into pipeline development, and enables the production of homogeneous antibody glycoforms with optimized bioactivity.
GlycoT’s Expertise
GlycoT Therapeutics specializes in applying its chemo-enzymatic glycosylation technology to engineer therapeutic proteins, including mAbs, for improved therapeutic efficacy. The company also focuses on developing novel enzymatic methods and precision antibody-drug conjugation.-Fineline Info & Tech